Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Translational Study for Obesity Management in Mexican Adults Using the "Group Lifestyle Balance Program" (GLBOMEX)

20 maj 2016 uppdaterad av: Rolando Giovanni Díaz Zavala, Universidad de Sonora

Translational Study for Overweight and Obesity Management in Adults Using the "Group Lifestyle Balance Program" in Primary Care Clinics and Public Hospitals From Sonora, México

Obesity is the main modifiable risk factor for the development of chronic diseases in Mexico. Several randomized controlled trials have shown that intensive lifestyle programs are efficacious for the management of obesity. These programs include frequent sessions (14 or more contacts in the first 6 months) focused on diet and physical activity and use a behavior change protocol. In Mexico most primary care clinics and public hospitals apply traditional treatments for obesity management, which have limited effect on weight loss. This study would provide scientific evidence for an effective model for obesity management. Objective. The purpose of this study is to evaluate the effectiveness of the "Group Lifestyle Balance Program" for overweight and obesity management in adults, in primary care clinics and public hospitals from Sonora. This is a translational clinical study. Healthcare providers from the participating clinics will be trained with the Group Lifestyle Balance Program before its implementation. The primary outcome measurement is the change in body weight from baseline to 6 months and 12 months. Changes in body mass index, waist circumference, systolic and diastolic blood pressure, depression, quality of life and stress scales will be measured in patients receiving the program before and 6 and 12 months after starting the program. Additionally, biochemical parameters (fasting glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, fasting insulin, Homeostatic Model Assessment- Insulin Resistance (HOMA-IR) and liver enzymes [Aspartate transaminase (AST), Alanine Aminotransferase (ALT)] will be evaluated from baseline to 12 months.

Studieöversikt

Status

Okänd

Betingelser

Studietyp

Interventionell

Inskrivning (Faktisk)

258

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Sonora
      • Hermosillo, Sonora, Mexiko, 83000
        • Centro de Promoción de Salud Nutricional (CPSN)
      • Hermosillo, Sonora, Mexiko, 83000
        • Centro de Salud Urbano Dr. Domingo Olivares
      • Hermosillo, Sonora, Mexiko, 83000
        • Hospital General del Estado de Sonora
      • Hermosillo, Sonora, Mexiko, 83000
        • Hospital Ignacio Chávez
      • Hermosillo, Sonora, Mexiko, 83180
        • Centro Avanzado de Atención a la Salud (CAAPS)

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Adults (>18 years of age and <65)
  • Overweight or Obese (BMI >25 kg/m2 y <50 kg/m2)
  • Availability and motivation to attend the intervention program
  • Patients who would benefit from participating in the program according to the health providers
  • Signing an informed consent

Exclusion Criteria:

  • Medical conditions affecting body weight significantly
  • Pregnancy or nursing
  • Bariatric surgery
  • Being unable to participate in regular moderate physical activity
  • Blood pressure >160 mm/Hg
  • HbA1c>9

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Group Lifestyle Balance Program

Participants will be assigned to an adaptation of the "Group Lifestyle Balance Program", a behavioral curriculum implemented in the Diabetes Prevention Program Study. The Group Lifestyle Balance Program will be provided weekly for the first 3.5 months, bi-weekly from 3.5 to 6 months and then monthly until 12 months. Health care providers will be trained for the implementation of the intervention.

Additionally, participants will attend at least one monthly visit with a nutritionist (individually).

The lifestyle objectives for participants will be as follows:

  1. To lose 5-10% of initial weight through healthy eating.
  2. To do 150 minutes of physical activity each week.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Change in body weight
Tidsram: Change in body weight from baseline to 6 months and change in body weight from baseline to 12 months
Change in body weight from baseline to 6 months and change in body weight from baseline to 12 months

Sekundära resultatmått

Resultatmått
Tidsram
Change in waist circumference
Tidsram: Change in waist circumference from baseline to 6 months and change in waist circumference from baseline to 12 months
Change in waist circumference from baseline to 6 months and change in waist circumference from baseline to 12 months
Change in body fat percentage
Tidsram: Change in body fat percentage from baseline to 6 months and change in body fat percentage from baseline to 12 months
Change in body fat percentage from baseline to 6 months and change in body fat percentage from baseline to 12 months
Change in the Beck Depression Inventory score
Tidsram: Change in the Beck Depression Inventory score from baseline to 6 months and change in in the Beck Depression Inventory score from baseline to 12 months
Change in the Beck Depression Inventory score from baseline to 6 months and change in in the Beck Depression Inventory score from baseline to 12 months
Change in the Short Form-36 Health Survey score
Tidsram: Change in the Short Form-36 Health Survey score from baseline to 6 months and change in the SF-36 Health Survey score from baseline to 12 months
Change in the Short Form-36 Health Survey score from baseline to 6 months and change in the SF-36 Health Survey score from baseline to 12 months
Change in the Perceived Stress Scale (PSS) -14 score
Tidsram: Change in the Perceived Stress Scale (PSS) -14 score from baseline to 6 months and change in the Perceived Stress Scale PSS-14 score from baseline to 12 months
Change in the Perceived Stress Scale (PSS) -14 score from baseline to 6 months and change in the Perceived Stress Scale PSS-14 score from baseline to 12 months
Change in systolic and diastolic blood pressure
Tidsram: Change in systolic and diastolic blood pressure from baseline to 6 months and change in systolic and diastolic blood pressure from baseline to 12 months
Change in systolic and diastolic blood pressure from baseline to 6 months and change in systolic and diastolic blood pressure from baseline to 12 months
Change in fasting glucose
Tidsram: Change in fasting glucose from baseline to 12 months
Change in fasting glucose from baseline to 12 months
Change in total cholesterol
Tidsram: Change in total colesterol from baseline to 12 months
Change in total colesterol from baseline to 12 months
Change in LDL-cholesterol
Tidsram: Change in LDL-cholesterol from baseline to 12 months
Change in LDL-cholesterol from baseline to 12 months
Change in HDL-cholesterol
Tidsram: Change in HDL-cholesterol from baseline to 12 months
Change in HDL-cholesterol from baseline to 12 months
Change in triglycerides
Tidsram: Change in triglycerides from baseline to 12 months
Change in triglycerides from baseline to 12 months
Change in fasting insulin
Tidsram: Change in fasting insulin from baseline to 12 months
Change in fasting insulin from baseline to 12 months
Change in HOMA-IR
Tidsram: Change in HOMA-IR from baseline to 12 months
Change in HOMA-IR from baseline to 12 months
Change in liver enzymes [AST and ALT]
Tidsram: Change in liver enzymes [AST and ALT] from baseline to 12 months
Change in liver enzymes [AST and ALT] from baseline to 12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Rolando G Díaz, Ph.D., Universidad de Sonora

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 september 2015

Primärt slutförande (Förväntat)

1 april 2017

Avslutad studie (Förväntat)

1 april 2017

Studieregistreringsdatum

Först inskickad

25 augusti 2015

Först inskickad som uppfyllde QC-kriterierna

28 augusti 2015

Första postat (Uppskatta)

2 september 2015

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

23 maj 2016

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

20 maj 2016

Senast verifierad

1 maj 2016

Mer information

Termer relaterade till denna studie

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera